<DOC>
	<DOC>NCT01136824</DOC>
	<brief_summary>Assessments (survey data) in this study are designed to sample the symptom burden of patients undergoing adjuvant and neoadjuvant chemotherapy in the hospital. There will be no change in the treatment plan for these patients.</brief_summary>
	<brief_title>Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Patients who are receiving doxorubicin plus ifosfamide (AI) There is no exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>questionnaire</keyword>
	<keyword>doxorubicin plus ifosfamide (AI)</keyword>
</DOC>